ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1721

Recombinant Zoster Vaccine Uptake in US Adults with Rheumatic Disease: A Mixed Methods Analysis
Abstract Number: 1722

Machine Learning-based Risk Stratification Tool to Predict Early Flare for Rheumatic and Musculoskeletal Diseases
Abstract Number: 1723

Clustering Analysis with Unsupervised Machine Learning Process to Phenotype the Cardiovascular Risk of Patients with Rheumatoid Arthritis Beyond the 10-year Prediction Algorithm
Abstract Number: 1724

Performance of a Novel Cardiovascular Risk Calculator in Rheumatoid Arthritis
Abstract Number: 1725

Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Abstract Number: 1726

Safety, Cancer Progression, and Autoimmune Disease Activity in Patients with Pre-Existing Autoimmune Disease Undergoing CD19 CAR T Cell Therapy for Lymphoma: A Retrospective Comparative Cohort Study
Abstract Number: 1727

Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab
Abstract Number: 1728

Higher Oral Steroid Dose Is Associated with Worse Survival in Immune Checkpoint Inhibitor-Treated Rheumatoid Arthritis Patients with Metastatic Non-Small Cell Lung Cancer
Abstract Number: 1729

Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Abstract Number: 1730

Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors
Abstract Number: 1731

Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial
Abstract Number: 1732

In Vitro Screening of siRNAs Designed to Knockdown Interferon Beta as a Novel Therapeutic Approach for Treatment of Adult and Juvenile Dermatomyositis
Abstract Number: 1733

Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Abstract Number: 1734

Safety and Efficacy Data from a Phase I Trial of Umbilical Lining-Derived Stem Cells (ULSC) in Adult Dermatomyositis/Polymyositis
Abstract Number: 1735

High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].